Vertex Pharmaceuticals Financial Diagnostics

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

USD 234.61  5.55  2.42%

The latest bullish price patterns experienced by current Vertex Pharmaceuticals shareholders may raise some interest from investors as it closed today at a share price of 234.4 on 1112977.000 in trading volume. The company directors and management have been very successful with rebalancing the company assets at opportune times to take advantage of market volatility in December. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.22. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. This diagnostics interface makes it easy to digest most current publicly released information about Vertex Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Vertex Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency. Also please take a look at World Market Map.

Vertex Pharmaceuticals Note

About 99.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.65. Vertex Pharmaceuticals recorded earning per share (EPS) of 8.24. The entity had not issued any dividends in recent years. The firm had 2:1 split on 2000-08-24. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people. For more information please call Jeffrey Leiden at 617 341-6100 or visit www.vrtx.com.

Vertex Pharmaceuticals Alerts

Over 99.0% of the company outstanding shares are owned by institutional investors
Latest headline from MacroaxisInsider: Sale by Paul Silva of 750 shares of Vertex Pharmaceuticals

Vertex Pharmaceuticals Upcoming and Recent Events

Upcoming Quarterly Earning ReportFebruary 4, 2020
Next Earnings ReportMay 5, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 4, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Vertex Pharmaceuticals Earning Estimates

EPSEstimate Date
Quarterly Estimate0.95February 4, 2020
Vertex Pharmaceuticals Incorpor normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Vertex Pharmaceuticals SEC Filings

Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Entry into a Material Definitive Agreement

Vertex Pharmaceuticals Thematic Classifications

Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Institutional Investors

Security TypeSharesValue
Assenagon Asset Management SaCommon Shares269.4 K59 M
Manning Napier Group LlcCommon Shares219.2 K48 M
Welch Forbes LlcCommon Shares174.9 K38.3 M
Rhenman Partners Asset Management AbCommon Shares160 K35 M
Gateway Investment Advisers LlcCommon Shares145 K31.8 M
Peregrine Capital Management LlcCommon Shares130.6 K28.6 M
Trinity Street Asset Management LlpCommon Shares116.6 K25.5 M

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 55.96 B.

Profitablity

The company has Profit Margin (PM) of 0.31 % which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 25.01 % which suggests for every 100 dollars of sales it generated a net operating income of 0.25.

Stock Holders for Vertex Pharmaceuticals

Information
Ratio
Value
At Risk
NASDAQ 100 Notional Net Total R 0.06 (1.29) 
NASDAQ 100 Total Return Index 0.15 (1.31) 
NASDAQ Biotechnology Total Retu(0.0081) (1.93) 
NASDAQ Composite Total Return I 0.06 (0.91) 
NASDAQ 100 Pre Market Indicator 0.06 (0.58) 
NASDAQ 100 After Hours Indicato 0.06 (1.53) 
Nasdaq Yewno Global Disruptive(0.02) (0.70) 
NASDAQ 100 Reduced Value Index 0.06 (1.31) 
NASDAQ US Large Mid Cap Index 0.0069 (1.14) 
NASDAQ N America Large Mid Cap(0.0242) (0.87) 
NASDAQ Global Select Market Com 0.1 (0.60) 
Nasdaq Future Global Sustainabi 0.07 (0.92) 
Nasdaq Factor Family US Growth 0.11 (1.35) 
Nasdaq CRD Global Sustainabilit 0.11 (0.48) 
Nasdaq CRD Global Sustainabilit(0.0304) (0.97) 
NASDAQ 100 Ex Tech Sector 0.0347 (1.14) 
NASDAQ 100 Equal Weighted 0.12 (1.15) 
Nasdaq 100 Index CHF 0.0003 (1.35) 
NASDAQ 100 0.15 (1.32) 
NASDAQ Biotechnology JPY(0.11) (2.30) 

Technical Drivers

As of the 25th of January Vertex Pharmaceuticals has Semi Deviation of 0.3038, Coefficient Of Variation of 335.13 and Risk Adjusted Performance of 0.1485. In relation to Fundamental Indicators, Macroaxis technical analysis interface makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals as well as the relationship between them. In other words you can use this information to find out if the company will indeed mirror its model of past prices and volume data or the prices will eventually revert. We found nineteen technical drivers for Vertex Pharmaceuticals Incorpor which can be compared to its competition. Please validate Vertex Pharmaceuticals Value At Risk as well as the relationship between Semi Variance and Kurtosis to decide if Vertex Pharmaceuticals is priced more or less accurately providing market reflects its prevalent price of 234.61 per share. Given that Vertex Pharmaceuticals has Jensen Alpha of 0.2799, we advise you double-check Vertex Pharmaceuticals Incorpor current market performance to make sure the company can sustain itself at future point.

Vertex Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Moving Average is predictive technique used to analyze Vertex Pharmaceuticals price data points by creating a series of averages of different subsets of Vertex Pharmaceuticals entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Vertex Pharmaceuticals Insider Trading Activities

Paul Silva 2 days ago via Macroaxis 
Sale by Paul Silva of 750 shares of Vertex Pharmaceuticals
Sanders Charles A 3 days ago via Macroaxis 
Exercise or conversion by Sanders Charles A of 3000 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Amit Sachdev few days ago via Macroaxis 
Exercise or conversion by Amit Sachdev of 5000 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Kelly Lisa few days ago via Macroaxis 
Exercise or conversion by Kelly Lisa of 953 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Bruce Sachs six days ago via Macroaxis 
Purchase by Bruce Sachs of 1600 shares of Vertex Pharmaceuticals
Bruce Sachs over a week ago via Macroaxis 
Acquisition by Bruce Sachs of 200 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Joshua Boger over a week ago via Macroaxis 
Acquisition by Joshua Boger of 7100 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Michael Parini over a week ago via Macroaxis 
Exercise or conversion by Michael Parini of 2125 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Michael Parini over a week ago via Macroaxis 
Sale by Michael Parini of 300 shares of Vertex Pharmaceuticals
Joshua Boger over a week ago via Macroaxis 
Vertex Pharmaceuticals exotic insider transaction detected
Joshua Boger over a week ago via Macroaxis 
Exercise or conversion by Joshua Boger of 17500 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Tatsis Ourania over two weeks ago via Macroaxis 
Exercise or conversion by Tatsis Ourania of 1675 shares of Vertex Pharmaceuticals subject to Rule 16b-3

Vertex Pharmaceuticals Technical and Predictive Indicators

Vertex Pharmaceuticals Forecast Models

Recommendations

Vertex Pharmaceuticals Analyst Recommendations

Target PriceAdvice# of Analysts
243.07Buy15Odds
Vertex Pharmaceuticals Incorpor current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Vertex Pharmaceuticals Analyst Advice  

Vital Value Indicators

Vertex Pharmaceuticals Basic Pricing Drivers

Quick Ratio3.20
Fifty Two Week Low163.68
Revenue Growth21.10%
Shares Short Prior Month3.95M
Average Daily Volume Last 10 Day1.43M
Average Daily Volume In Three Month1.4M
Earnings Growth-55.60%
Shares Percent Shares Out1.40%
Gross Margins39.29%
Earnings Quarterly Growth-55.30%
Short Percent Of Float1.56%
Forward Price Earnings35.15
Float Shares256.82M
Fifty Two Week High236.51
Enterprise Value To Ebitda63.29
Fifty Day Average223.13
Two Hundred Day Average193.19
Enterprise Value To Revenue15.83
Also please take a look at World Market Map. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.
Company logos by clearbit